Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma.

Abstract excerpt

Mutations in the KRAS gene are the most common gain-of-function mutations found in lung adenocarcinomas. The most prevalent mutation, KRAS G12C, occurs in 13% of lung adenocarcinomas. Sotorasib is an irreversible small molecule inhibitor that targets KRAS G12C. Previous studies have shown that treatment with sotorasib leads to the regression of KRAS G12C-mutated tumours. However, KRAS G12C often occurs alongside...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenocarcinoma of Lung
• Share to Antineoplastic Combined Chemotherapy Protocols